Sandbox:skorjian2: Difference between revisions
Jump to navigation
Jump to search
Sergekorjian (talk | contribs) No edit summary |
Sergekorjian (talk | contribs) No edit summary |
||
Line 77: | Line 77: | ||
| ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease||2012||Vitamin C, vitamin E, and beta-carotene supplementation are not recommended with the intent of reducing cardiovascular risk or improving clinical outcomes in patients with SIHD||A||No Benefit||Stable ischemic heart disease | | ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease||2012||Vitamin C, vitamin E, and beta-carotene supplementation are not recommended with the intent of reducing cardiovascular risk or improving clinical outcomes in patients with SIHD||A||No Benefit||Stable ischemic heart disease | ||
|- | |- | ||
| ACC/AHA/HRS Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities||||Permanent pacing is not indicated for torsade de pointes VT due to reversible causes.||A||N/A||Cardiac Rhythm Abnormalities | | ACC/AHA/HRS Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities||2008||Permanent pacing is not indicated for torsade de pointes VT due to reversible causes.||A||N/A||Cardiac Rhythm Abnormalities | ||
|- | |- | ||
| AHA Scientific Statement: Secondary Prevention After Coronary Artery Bypass Graft Surgery||2015||Among patients with LV dysfunction (EF <35%), ICD therapy is not recommended for the prevention of sudden cardiac death after CABG until 3 months of postoperative goal-directed medical therapy has been provided and persistent LV dysfunction has been confirmed ||A||N/A||CABG | | AHA Scientific Statement: Secondary Prevention After Coronary Artery Bypass Graft Surgery||2015||Among patients with LV dysfunction (EF <35%), ICD therapy is not recommended for the prevention of sudden cardiac death after CABG until 3 months of postoperative goal-directed medical therapy has been provided and persistent LV dysfunction has been confirmed ||A||N/A||CABG |
Revision as of 20:39, 4 May 2015
Title of Guidelines | Year | Class III Recommendation | Level of Evidence | Effect | Key Word |
---|---|---|---|---|---|
ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery | 2014 | Routine use of pulmonary artery catheterization in patients, even those with elevated risk, is not recommended. | A | No Benefit | Cardiac evaluation for non cardiac surgery |
ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery | 2009 | Routine use of a PAC perioperatively, especially in patients at low risk of developing hemodynamic disturbances, is not recommended. | A | N/A | Perioperative Beta Blockade |
ACCF/AHA Guideline for the Management of Heart Failure | 2013 | Statins are not beneficial as adjunctive therapy when prescribed solely for the diagnosis of HF in the absence of other indications for their use. | A | No Benefit | Heart failure |
ACCF/AHA Guideline for the Management of Heart Failure | 2013 | Calcium channel–blocking drugs are not recommended as routine treatment for patients with HFrEF | A | No Benefit | Heart failure |
ACCF/AHA Guideline for the Management of Heart Failure | 2013 | Statins are not beneficial as adjunctive therapy when prescribed solely for the diagnosis of HF in the absence of other indications for their use. | A | No Benefit | Heart failure |
ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease | 2012 | Estrogen therapy is not recommended in postmenopausal women with SIHD with the intent of reducing cardiovascular risk or improving clinical outcomes. | A | No Benefit | Ischemic heart disease |
ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease | 2012 | Treatment of elevated homocysteine with folate or vitamins B6 and B12 is not recommended with the intent of reducing cardiovascular risk or improving clinical outcomes in patients with SIHD. | A | No Benefit | Ischemic heart disease |
ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease | 2012 | Vitamin C, vitamin E, and beta-carotene supplementation are not recommended with the intent of reducing cardiovascular risk or improving clinical outcomes in patients with SIHD. | A | No Benefit | Ischemic heart disease |
ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention | 2011 | Administration of N-acetyl-L-cysteine is not useful for the prevention of contrast-induced acute kidney injury. | A | No Benefit | PCI |
ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention | 2011 | Cutting balloon angioplasty should not be performed routinely during PCI. | A | No Benefit | PCI |
ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention | 2011 | Laser angioplasty should not be used routinely during PCI. | A | No Benefit | PCI |
ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention | 2011 | Rotational atherectomy should not be performed routinely for de novo lesions or in-stent restenosis. | A | No Benefit | PCI |
AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes | 2014 | Antioxidant vitamin supplements (eg, vitamins E, C, or beta carotene) should not be used for secondary prevention in patients with NSTE-ACS. | A | No Benefit | NSTEMI |
AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes | 2014 | Folic acid, with or without vitamins B6 and B12, should not be used for secondary prevention in patients with NSTE-ACS. | A | No Benefit | NSTEMI |
AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes | 2014 | Hormone therapy with estrogen plus progestin, or estrogen alone, should not be given as new drugs for secondary prevention of coronary events to postmenopausal women after NSTE-ACS and should not be continued in previous users unless the benefits outweigh the estimated risks. | A | Harm | NSTEMI |
AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes | 2014 | In patients with NSTE-ACS (ie, without ST-elevation, true posterior Ml, or left bundle-branch block not known to be old), intravenous fibrinolytic therapy should not be used. | A | Harm | NSTEMI |
AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes | 2014 | With contemporary troponin assays, creatine kinase myocardial isoenzyme (CK-MB) and myoglobin are not useful for diagnosis of ACS. | A | No Benefit | NSTEMI |
AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease | 2014 | Statin therapy is not indicated for prevention of hemodynamic progression of AS in patients with mild-to-moderate calcific valve disease (stages B to D). | A | No Benefit | Valvular heart disease |
AHA Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science | 2010 | Management of Arrhythmias,Ventricular Rhythm Disturbances Prophylactic administration of lidocaine is not recommended | A | N/A | Cardiopulmonary Resuscitation |
AHA Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science | 2010 | Management of Arrhythmias,Ventricular Rhythm Disturbances Pprophylactic antiarrhythmics are not recommended for patients with suspected ACS or myocardial infarction in the prehospital or ED | A | N/A | Cardiopulmonary Resuscitation |
AHA Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science | 2010 | Cardiac Arrest Associated With Pulmonary Embolism In patients with cardiac arrest and without known PE, routine fibrinolytic treatment given during CPR shows no benefit185,186 and is not recommended | A | N/A | Cardiopulmonary Resuscitation |
AHA Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science | 2010 | Other Vasopressors,Magnesium Sulfate Routine administration of magnesium sulfate in cardiac arrest is not recommended unless torsades de pointes is present. | A | N/A | Cardiopulmonary Resuscitation |
ACC/AHA Guidelines for the Management of Adults With Congenital Heart Disease | 2008 | Pregnancy in patients with ASD and severe PAH (Eisenmenger syndrome) is not recommended owing to excessive maternal and fetal mortality and should be strongly discouraged. | A | N/A | Congenital heart disease |
ACC/AHA Guidelines for the Management of Adults With Congenital Heart Disease | 2008 | Pregnancy in patients with VSD and severe PAH (Eisenmenger syndrome) is not recommended owing to excessive maternal and fetal mortality and should be strongly discouraged. | A | N/A | Congenital heart disease |
ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery | 2014 | Routine use of pulmonary artery catheterization in patients, even those with elevated risk, is not recommended. | A | No Benefit | Cardiac risk evaluation for non-cardiac surgery |
ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults | 2013 | CK should not be routinely measured in individuals receiving statin therapy. | A | No benefit | Dyslipidemia |
ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults | 2013 | It may be harmful to initiate simvastatin at 80 mg daily or increase the dose of simvastatin to 80 mg daily. | A | Harm | Dyslipidemia |
ACC/AHA Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic) | 2005 | Chelation (e.g., ethylenediaminetetraacetic acid) is not indicated for treatment of intermittent claudication and may have harmful adverse effects. | A | N/A | Peripheral arterial disease |
ACC/AHA Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic) | 2005 | Intervention is not recommended for asymptomatic infrarenal or juxtarenal AAAs if they measure less than 5.0 cm in diameter in men or less than 4.5 cm in diameter in women. | A | N/A | Peripheral arterial disease |
ACC/AHA Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic) | 2005 | Oral vasodilator prostaglandins such as beraprost and iloprost are not effective medications to improve walking distance in patients with intermittent claudication. | A | N/A | Peripheral arterial disease |
ACC/AHA/ESC Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death | 2006 | Class IC antiarrhythmic drugs in patients with a past history of MI should not be used. | A | No Benefit | Ventricular arrhythmias |
ACC/AHA/HRS Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities | 2008 | Permanent pacing is not indicated for torsade de pointes VT due to reversible causes. | A | N/A | Device-based therapy |
ACCF/AHA Guideline for the Management of Heart Failure | 2013 | Calcium channel–blocking drugs are not recommended as routine treatment for patients with HFrEF. | A | No Benefit | Heart Failure |
ACCF/AHA Guideline for the Management of Heart Failure | 2013 | Statins are not beneficial as adjunctive therapy when prescribed solely for the diagnosis of HF in the absence of other indications for their use | A | No Benefit | Heart Failure |
ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease | 2012 | Vitamin C, vitamin E, and beta-carotene supplementation are not recommended with the intent of reducing cardiovascular risk or improving clinical outcomes in patients with SIHD | A | No Benefit | Stable ischemic heart disease |
ACC/AHA/HRS Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities | 2008 | Permanent pacing is not indicated for torsade de pointes VT due to reversible causes. | A | N/A | Cardiac Rhythm Abnormalities |
AHA Scientific Statement: Secondary Prevention After Coronary Artery Bypass Graft Surgery | 2015 | Among patients with LV dysfunction (EF <35%), ICD therapy is not recommended for the prevention of sudden cardiac death after CABG until 3 months of postoperative goal-directed medical therapy has been provided and persistent LV dysfunction has been confirmed | A | N/A | CABG |
AHA Scientific Statement: Secondary Prevention After Coronary Artery Bypass Graft Surgery | 2015 | Warfarin should not be routinely prescribed after CABG for graft patency unless patients have other indications for long-term antithrombotic therapy (such as AF, venous thromboembolism, or a mechanical prosthetic valve) | A | N/A | CABG |
AHA Scientific Statement: Diagnosis and Treatment of Fetal Cardiac Disease | 2014 | Fetal medical therapy is of no benefit for fetuses with sinus bradycardia, irregular rhythms caused by extrasystolic beats. | A | N/A | Fetal cardiac disease |
AHA Scientific Statement: Diagnosis and Treatment of Fetal Cardiac Disease | 2014 | Referral for fetal cardiac evaluation is not indicated for maternal medications including SSRIs (other than paroxetine). | A | N/A | Fetal cardiac disease |
AHA Scientific Statement: Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension | 2011 | Systemic fibrinolysis should not be given routinely to patients with IFDVT. | A | N/A | Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension |
AHA Scientific Statement: The Postthrombotic Syndrome Evidence-Based Prevention, Diagnosis, and Treatment Strategies | 2014 | Recommendations for Thrombolysis and Endovascular Approaches to Acute DVT for the Prevention of PTS Systemic thrombolysis is not recommended for the treatment of DVT | A | N/A | Postthrombotic Syndrome |
AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes | 2014 | Antioxidant vitamin supplements (eg, vitamins E, C, or beta carotene) should not be used for secondary prevention in patients with NSTE-ACS. | A | No Benefit | NSTEMI |
AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes | 2014 | Folic acid, with or without vitamins B6 and B12, should not be used for secondary prevention in patients with NSTE-ACS. | A | No Benefit | NSTEMI |
AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes | 2014 | Hormone therapy with estrogen plus progestin, or estrogen alone, should not be given as new drugs for secondary prevention of coronary events to postmenopausal women after NSTE-ACS and should not be continued in previous users unless the benefits outweigh the estimated risks. | A | Harm | NSTEMI |
AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes | 2014 | In patients with NSTE-ACS (ie, without ST-elevation, true posterior MI, or left bundle-branch block not known to be old), intravenous fibrinolytic therapy should not be used. | A | Harm | NSTEMI |
AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes | 2014 | With contemporary troponin assays, creatine kinase myocardial isoenzyme (CK-MB) and myoglobin are not useful for diagnosis of ACS. | A | No Benefit | NSTEMI |
AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease | 2014 | Statin therapy is not indicated for prevention of hemodynamic progression of AS in patients with mild-to-moderate calcific valve disease (stages B to D). | A | No Benefit | Valvular heart disease |
AHA Scientific Statement: Cardiac Disease Evaluation and Management Among Kidney and Liver Transplantation Candidates | 2012 | Initiating beta-blocker therapy in beta-blocker–naïve patients the night before and/or the morning of noncardiac surgery is not recommended | A | N/A | Kidney and Liver Transplantation Candidates |
Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease | 2011 | Except in extraordinary circumstances, carotid revascularization by either CEA or CAS is not recommended when atherosclerosis narrows the lumen by less than 50%. | A | No Benefit | Extracranial Carotid and Vertebral Artery Disease |
AHA/ASA Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack | 2014 | For patients with a cryptogenic ischemic stroke or TIA and a PFO without evidence for DVT, available data do not support a benefit for PFO closure | A | N/A | Prevention of stroke |
AHA/ASA Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack | 2014 | For patients with a recent (within 6 months) TIA or ischemic stroke ipsilateral to a stenosis or occlusion of the middle cerebral or carotid artery, EC/IC bypass surgery is not recommended | A | N/A | Prevention of stroke |
AHA/ASA Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack | 2014 | Routine supplementation with a single vitamin or combination of vitamins is not recommended | A | N/A | Prevention of stroke |
AHA/ASA Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack | 2014 | The combination of aspirin and clopidogrel, when initiated days to years after a minor stroke or TIA and continued for 2 to 3 years, increases the risk of hemorrhage relative to either agent alone and is not recommended for routine long-term secondary prevention after ischemic stroke or TIA | A | N/A | Prevention of stroke |
AHA/ASA Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack | 2014 | When the degree of stenosis is <50%, CEA and CAS are not recommended | A | N/A | Prevention of stroke |
AHA/ASA Guidelines for the Primary Prevention of Stroke | 2011 | Aspirin is not useful for preventing a first stroke in persons at low risk | A | N/A | Primary prevention of stroke |
AHA/ASA Guidelines for the Primary Prevention of Stroke | 2011 | Hormone therapy (CEE with or without MPA) should not be used for primary prevention of stroke in postmenopausal women | A | N/A | Primary prevention of stroke |
AHA/ASA Guidelines for the Primary Prevention of Stroke | 2011 | Screening for cardiac conditions such as PFO in the absence of neurological conditions or a specific cardiac cause is not recommended | A | N/A | Primary prevention of stroke |
AHA/ASA Guidelines for the Primary Prevention of Stroke | 2011 | SERMs, such as raloxifene, tamoxifen, or tibolone, should not be used for primary prevention of stroke | A | N/A | Primary prevention of stroke |
AHA/ASA Guidelines for the Primary Prevention of Stroke | 2011 | Treatment with antibiotics for chronic infections as a means to prevent stroke is not recommended | A | N/A | Primary prevention of stroke |
ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery | 2009 | Routine use of a PAC perioperatively, especially in patients at low risk of developing hemodynamic disturbances, is not recommended. | A | N/A | Perioperative Beta Blockade |
ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease | 2012 | Estrogen therapy is not recommended in postmenopausal women with SIHD with the intent of reducing cardiovascular risk or improving clinical outcomes. | A | No Benefit | Stable ischemic heart disease |
ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease | 2012 | Treatment of elevated homocysteine with folate or vitamins B6 and B12 is not recommended with the intent of reducing cardiovascular risk or improving clinical outcomes in patients with SIHD | A | No Benefit | Stable ischemic heart disease |